How Tempus AI Is Advancing Toward Regulatory Pricing Catch-Up [Yahoo! Finance]
Doximity, Inc. Class A (DOCS)
Company Research
Source: Yahoo! Finance
The company has several structural catalysts that could help narrow this pricing gap over time. Tempus exited the quarter with approximately one-third of xT CDx volume already on the FDA-approved or Advanced Diagnostic Laboratory Test (ADLT) pathway. Management also expects to submit the xF assay for FDA approval by the end of 2025, which would make it eligible for ADLT status, with the xR assay expected to follow. MRD reimbursement is progressing as planned and is expected to scale gradually, while regulatory submissions and ADLT migrations through 2025–2026 outline a clear path to improving pricing and unit economics. While the strategic roadmap is clear, execution risk remains elevated, given the dependence on regulatory review timelines. The magnitude and cadence of ADLT-related pricing uplift will not be known until approvals are secured, leaving near-term per-test economics below peer levels. Prolonged reviews, reimbursement delays, or adverse payer policy changes could de
Show less
Read more
Impact Snapshot
Event Time:
DOCS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DOCS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DOCS alerts
High impacting Doximity, Inc. Class A news events
Weekly update
A roundup of the hottest topics
DOCS
News
- Doximity to Release Fiscal 2026 Third Quarter Results on February 5, 2026Business Wire
- Raymond James Sees ‘Knee-Jerk' AI Reaction, Reaffirms Strong Buy on Doximity, Inc. (DOCS) [Yahoo! Finance]Yahoo! Finance
- Is Doximity (DOCS) Pricing Reflect Its Mixed Valuation Signals After Recent Share Price Slide [Yahoo! Finance]Yahoo! Finance
- Doximity (DOCS) Slid on Renewed Volatility [Yahoo! Finance]Yahoo! Finance
- Doximity (NYSE:DOCS) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "strong sell" rating to a "hold" rating.MarketBeat
DOCS
Earnings
- 11/6/25 - Beat
DOCS
Sec Filings
- 1/6/26 - Form 4
- 1/2/26 - Form 144
- 12/30/25 - Form 8-K
- DOCS's page on the SEC website